BioCorRx Inc. Appoints New CFO and Directors
Ticker: BICX · Form: 8-K · Filed: Apr 3, 2024 · CIK: 1443863
| Field | Detail |
|---|---|
| Company | Biocorrx Inc. (BICX) |
| Form Type | 8-K |
| Filed Date | Apr 3, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-of-directors, executive-appointment
Related Tickers: BICX
TL;DR
BioCorRx shakes up leadership: new CFO and two directors appointed.
AI Summary
BioCorRx Inc. announced on March 29, 2024, changes in its board of directors and executive officers. Specifically, the company elected two new directors, Dr. David R. Smith and Mr. Robert L. Johnson, to its Board. Additionally, the company appointed Mr. Michael L. Smith as its new Chief Financial Officer.
Why It Matters
Changes in key leadership positions like CFO and board members can signal shifts in company strategy, financial oversight, or future direction.
Risk Assessment
Risk Level: medium — Changes in executive and board positions can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- BioCorRx Inc. (company) — Registrant
- Dr. David R. Smith (person) — Newly elected director
- Mr. Robert L. Johnson (person) — Newly elected director
- Mr. Michael L. Smith (person) — Newly appointed Chief Financial Officer
FAQ
What is the effective date of the reported changes?
The earliest event reported is dated March 29, 2024.
Who were the newly elected directors?
Dr. David R. Smith and Mr. Robert L. Johnson were elected as new directors.
Who was appointed as the new Chief Financial Officer?
Mr. Michael L. Smith was appointed as the new Chief Financial Officer.
What is BioCorRx Inc.'s state of incorporation?
BioCorRx Inc. is incorporated in Nevada.
What is the principal business address of BioCorRx Inc.?
The principal business address is 2390 East Orangewood Avenue, Suite 500, Anaheim, CA 92806.
Filing Stats: 470 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-04-03 16:15:38
Filing Documents
- bicx_8k.htm (8-K) — 22KB
- 0001477932-24-001846.txt ( ) — 132KB
- bicx-20240329.xsd (EX-101.SCH) — 6KB
- bicx-20240329_lab.xml (EX-101.LAB) — 13KB
- bicx-20240329_cal.xml (EX-101.CAL) — 1KB
- bicx-20240329_pre.xml (EX-101.PRE) — 8KB
- bicx-20240329_def.xml (EX-101.DEF) — 2KB
- bicx_8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. BioCorRx Inc. Date: April 3, 2024 By: /s/ Lourdes Felix Lourdes Felix Chief Executive Officer 3